## Distinguishing Type I from Type II Endometrial Cancer ### Molecular and Histopathological Basis **Key Point:** Type I (endometrioid) and Type II (serous/clear cell) endometrial cancers represent distinct molecular and histopathological entities with different etiologies, prognoses, and treatment responses. ### Comparison Table | Feature | Type I (Endometrioid) | Type II (Serous/Clear Cell) | | --- | --- | --- | | **Histology** | Well-differentiated glands, resembles normal endometrium | High-grade, papillary architecture, atypical nuclei | | **ER/PR Status** | ER/PR positive (estrogen-responsive) | ER/PR negative | | **Molecular Driver** | PTEN loss, KRAS/PIK3CA mutations, MSI | TP53 mutations, p53 overexpression | | **Precursor** | Endometrial hyperplasia → cancer | Atypical endometrial intraepithelial carcinoma (AEIC) | | **Grade at Presentation** | Often low-grade (G1–G2) | High-grade (G3) | | **Myometrial Invasion** | Variable, often superficial | Deep myometrial invasion (>50%) common | | **LVSI** | Less frequent | Frequent at presentation | | **Prognosis** | Better (if early-stage) | Poor, even if early-stage | | **Lynch Syndrome** | Associated (15–30% of cases) | Not associated | ### Why Option 2 (ER/PR Positivity) is Correct **High-Yield:** Estrogen receptor (ER) and progesterone receptor (PR) positivity is the single most reliable and clinically actionable discriminator between Type I and Type II endometrial cancers. Type I tumors are typically **ER/PR positive** (estrogen-dependent), while Type II tumors are **ER/PR negative** (hormone-independent). **Clinical Pearl:** ER/PR status directly guides treatment: - Type I (ER/PR+): Responsive to progestin therapy and endocrine manipulation in advanced/recurrent disease. - Type II (ER/PR−): Requires chemotherapy-based regimens; progestin therapy is ineffective. ### Supporting Features **Key Point:** Type I endometrioid cancers show well-differentiated glandular architecture resembling normal endometrium, whereas Type II serous/clear cell cancers display high-grade nuclear atypia, papillary growth, and loss of normal glandular differentiation. ### Molecular Context (Why Other Options Are Incomplete) - **Lynch syndrome and MSI** (Option 0): Associated with Type I, but not exclusive; not a discriminator for Type II. - **Myometrial invasion and LVSI** (Option 1): Type II shows these more frequently, but they are prognostic features, not diagnostic discriminators. - **TP53 mutations** (Option 3): Hallmark of Type II, but ER/PR status is more clinically accessible and actionable for treatment selection.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.